CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 3 enrolled
Drug / intervention
Crizotinibdrug
Likely dose
Crizotinib 250mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03088930
NCT03088930Phase 2Completed
CompareCT.gov

A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer

University of Colorado, Denver·interventional·Posted Mar 23, 2017·Updated Feb 11, 2022

In Brief

A Phase 2 clinical trial evaluating Crizotinib for Lung Cancer, Nonsmall Cell. Completed, enrolled 3 participants across 1 site.

Detailed Summary

This study will evaluate the efficacy of crizotinib as induction therapy in participants with surgically resectable ALK rearrangement, ROS1 rearrangement, or MET exon 14 mutation positive NSCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Nonsmall Cell
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 23, 2017
Enrollment StartDec 13, 2017
Primary CompletionJan 13, 2021
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.3 years ago

Interventions

Crizotinibdrug

Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.